Special aspects of concentrated insulins: basic characteristics and research findings

The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e. insulin lispro 200 units/mL, insulin degludec 200 unit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tatiana Y. Demidova, Olga V. Balutina
Formato:	article
Lenguaje:	EN RU
Publicado:	Endocrinology Research Centre 2019
Materias:	concentrated insulin diabetes mellitus euglycemic clamp reduce risk of hypoglycemia Nutritional diseases. Deficiency diseases RC620-627
Acceso en línea:	https://doaj.org/article/5e790a2b1f884b5e82137004d8de7387
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e790a2b1f884b5e82137004d8de7387
record_format	dspace
spelling	oai:doaj.org-article:5e790a2b1f884b5e82137004d8de73872021-11-14T09:00:22ZSpecial aspects of concentrated insulins: basic characteristics and research findings2072-03512072-037810.14341/DM10334https://doaj.org/article/5e790a2b1f884b5e82137004d8de73872019-12-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/10334https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e. insulin lispro 200 units/mL, insulin degludec 200 units/mL, insulin glargine 300 units/mL) from randomized controlled trials, derive guidance on appropriate and safe use of these agents and demonstrate experience in real clinical practice. Severe hypoglycemia in all studies was generally low (though higher with prandial plus concentrated basal analogue therapy), and statistical improvements in other hypoglycemia categories were observed for concentrated basal insulins versus insulin glargine 100 units/mL. In all analyzed data hypoglycemic effect of insulin glargine 300 units/mL was equitable to insulin glargine 100 units/mL. Other important findings demonstrate more constant and prolonged insulin action with low within-subject/ between-day variability for insulin glargine 300 units/mL versus insulin glargine 100 units/mL, therefore, more physiological treatment might prevent from diabetic microvascular complications. The results of randomized trials are comparable with our clinical practice experience and indicate efficacious and safe glucose-lowering properties without risk of severe hypoglycemia.Tatiana Y. DemidovaOlga V. BalutinaEndocrinology Research Centrearticleconcentrated insulindiabetes mellituseuglycemic clampreduce risk of hypoglycemiaNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 22, Iss 5, Pp 481-490 (2019)
institution	DOAJ
collection	DOAJ
language	EN RU
topic	concentrated insulin diabetes mellitus euglycemic clamp reduce risk of hypoglycemia Nutritional diseases. Deficiency diseases RC620-627
spellingShingle	concentrated insulin diabetes mellitus euglycemic clamp reduce risk of hypoglycemia Nutritional diseases. Deficiency diseases RC620-627 Tatiana Y. Demidova Olga V. Balutina Special aspects of concentrated insulins: basic characteristics and research findings
description	The appearance of concentrated insulins in clinical practice determines the need to analyze product priorities in appropriate groups of patients with diabetes. The aim of this article is to summarize the literature on concentrated insulins (i.e. insulin lispro 200 units/mL, insulin degludec 200 units/mL, insulin glargine 300 units/mL) from randomized controlled trials, derive guidance on appropriate and safe use of these agents and demonstrate experience in real clinical practice. Severe hypoglycemia in all studies was generally low (though higher with prandial plus concentrated basal analogue therapy), and statistical improvements in other hypoglycemia categories were observed for concentrated basal insulins versus insulin glargine 100 units/mL. In all analyzed data hypoglycemic effect of insulin glargine 300 units/mL was equitable to insulin glargine 100 units/mL. Other important findings demonstrate more constant and prolonged insulin action with low within-subject/ between-day variability for insulin glargine 300 units/mL versus insulin glargine 100 units/mL, therefore, more physiological treatment might prevent from diabetic microvascular complications. The results of randomized trials are comparable with our clinical practice experience and indicate efficacious and safe glucose-lowering properties without risk of severe hypoglycemia.
format	article
author	Tatiana Y. Demidova Olga V. Balutina
author_facet	Tatiana Y. Demidova Olga V. Balutina
author_sort	Tatiana Y. Demidova
title	Special aspects of concentrated insulins: basic characteristics and research findings
title_short	Special aspects of concentrated insulins: basic characteristics and research findings
title_full	Special aspects of concentrated insulins: basic characteristics and research findings
title_fullStr	Special aspects of concentrated insulins: basic characteristics and research findings
title_full_unstemmed	Special aspects of concentrated insulins: basic characteristics and research findings
title_sort	special aspects of concentrated insulins: basic characteristics and research findings
publisher	Endocrinology Research Centre
publishDate	2019
url	https://doaj.org/article/5e790a2b1f884b5e82137004d8de7387
work_keys_str_mv	AT tatianaydemidova specialaspectsofconcentratedinsulinsbasiccharacteristicsandresearchfindings AT olgavbalutina specialaspectsofconcentratedinsulinsbasiccharacteristicsandresearchfindings
_version_	1718429530495909888

Special aspects of concentrated insulins: basic characteristics and research findings

Ejemplares similares